- Home
- SRZN vs FBRX Comparison
SRZN vs FBRX Comparison
Compare SRZN & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- FBRX
- Stock Information
- Founded
- SRZN 2015
- FBRX N/A
- Country
- SRZN United States
- FBRX United States
- Employees
- SRZN N/A
- FBRX N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- FBRX Health Care
- Exchange
- SRZN Nasdaq
- FBRX Nasdaq
- Market Cap
- SRZN 72.8M
- FBRX 69.7M
- IPO Year
- SRZN N/A
- FBRX N/A
- Fundamental
- Price
- SRZN $8.71
- FBRX $10.55
- Analyst Decision
- SRZN Strong Buy
- FBRX Strong Buy
- Analyst Count
- SRZN 2
- FBRX 2
- Target Price
- SRZN $38.50
- FBRX $61.00
- AVG Volume (30 Days)
- SRZN 22.6K
- FBRX 185.0K
- Earning Date
- SRZN 08-11-2025
- FBRX 08-13-2025
- Dividend Yield
- SRZN N/A
- FBRX N/A
- EPS Growth
- SRZN N/A
- FBRX N/A
- EPS
- SRZN N/A
- FBRX N/A
- Revenue
- SRZN $11,638,000.00
- FBRX N/A
- Revenue This Year
- SRZN N/A
- FBRX N/A
- Revenue Next Year
- SRZN N/A
- FBRX N/A
- P/E Ratio
- SRZN N/A
- FBRX N/A
- Revenue Growth
- SRZN N/A
- FBRX N/A
- 52 Week Low
- SRZN $5.90
- FBRX $4.11
- 52 Week High
- SRZN $18.17
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- SRZN 47.45
- FBRX 44.73
- Support Level
- SRZN $8.00
- FBRX $10.15
- Resistance Level
- SRZN $8.94
- FBRX $13.20
- Average True Range (ATR)
- SRZN 0.72
- FBRX 1.89
- MACD
- SRZN -0.07
- FBRX -0.38
- Stochastic Oscillator
- SRZN 27.14
- FBRX 4.72
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).